Purpose of this Study
This study is trying to find out how well a new medicine called 4D-150 works compared to a medicine called Eylea in adults who have a kind of eye disease called wet age-related macular degeneration (wet AMD). The medicine is given as a shot directly into the eye. The study also wants to make sure the new medicine is safe and lasts a long time.
Who Can Participate?
Eligibility
People in this study must:
- Be 50 years old or older.
- Have never had treatment for their eye condition before.
- Have never had a problem called retinal detachment, which is when part of the eye pulls away from where it should be.
Age Range
50-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
People in this study will be part of it for about 110 weeks, which is a little more than 2 years. During that time, they will need to visit the study clinic at least 30 times. At each visit, they will have tests and check-ups that are part of their regular care and also for the study.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal
Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1) - 4D-150-C003
Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1) - 4D-150-C003
Principal Investigator
Majda
Hadziahmetovic
Protocol Number
PRO00117562
NCT ID
NCT06864988
Phase
III
Enrollment Status
Open to Enrollment